Protara Therapeutics, Inc. TARA
Updated: 10 Aug 2026
No signal published yet
We already track Protara Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Protara Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Protara Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 13, 2026, Protara Therapeutics reported its first quarter 2026 financial results and provided updated Phase 2 ADVANCED-2 trial data for TARA-002 in non-muscle invasive bladder cancer. The drug candidate demonstrated durable complete responses in 55% of BCG-naïve patients at 12 months. With $177.4 million in cash and investments, the company expects its funding runway to extend into 2028.
What Firelda Watch includes for Protara Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Protara Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Protara Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more